NCT02702388 · Interventional trial
A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile
Overall registry status Completed
Phase 2
Conditions Thyroid Cancer
Delaware Valley sites
- Facility #1 · Philadelphia, PA · Philadelphia County
- Facility #2 · Philadelphia, PA · Philadelphia County
First posted
Registry updated
Added to the directory